

Measure Name	Description	Details	BCBSM/BCN (PGIP, PCMH, VBR, PRP)	Priority Health (PIP)	ACO REACH
Annual Wellness Visit	BCBSM Medicare Plus Blue and BCN Advantage patients: Received a Medicare preventive visit	Only billed G codes satisfy Numerator: IPPE/Welcome to Medicare (G0402), First Visit AWV (G0438), or Subsequent AWV (G0439)	✓	n/a	n/a
Antidepressant Medication Management: Acute and Continuation Phase Treatment	Ages 18 years and older with Dx of Major Depression: Treated with antidepressant medication AND remained on medication treatment	Acute Phase: 12 weeks continuous Rx treatment; Continuation Phase: 6 months continuous Rx treatment	✓	n/a	n/a
Appropriate Testing for Pharyngitis	Ages 3 years and older: If Dx'd with Pharyngitis and antibiotic given, Group A Strep test done 3 days prior - 3 days after visit	Exclude pts. with competing/comorbid Dx on DOS, pts. on antibiotics within 30 days prior to DOS, pts. in hospice, or visits resulting in inpatient stays	<b>✓</b>	n/a	n/a
Appropriate Treatment for Upper Respiratory Infection	Ages 3 months and older: If Dx'd with URI, antibiotic Rx is NOT dispensed on, or within 3 days after, encounter	Inverse measure (lower Numerator is better); Exclude pts. with competing/comorbid Dx on DOS, pts. on antibiotics within 30 days prior to DOS, pts. in hospice, or visits resulting in inpatient stays	<b>√</b>	n/a	n/a
Asthma Medication Ratio - Total Ratio ≥ 50%	Ages 5–64 years with Dx of Persistent Asthma: Ratio of controller medications to total Asthma medications is $\geq$ 0.50	Numerator met by pharmacy claims for filled Rxs only; Exclude pts. with Emphysema, COPD, Cystic Fibrosis, Obstructive Chronic Bronchitis, Chronic Respiratory Conditions due to Fumes/Vapors, Acute Respiratory Failure, pts. In hospice	<b>√</b>	n/a	n/a
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis	Ages 3 months and older with Dx of Acute Bronchitis/Bronchiolitis: Antibiotic Rx was NOT dispensed on or within 3 days after encounter	Inverse measure (lower Numerator is better); Exclude pts. with competing/comorbid Dx on DOS, pts. on antibiotics within 30 days prior to DOS, pts. In hospice, or visits resulting in inpatient stays	<b>✓</b>	n/a	n/a
Breast Cancer Screening <sup>+</sup>	Females ages 50-74: One mammogram (screening, diagnostic, film or 3D) within 27 months (10/01/2021 - 12/31/2023)	ECDS-only measure beginning 01/01/2023. Exclude pts. with one bilateral or two unilateral mastectomies, in hospice or palliative care, or with both Frailty AND Advanced Illness (ages 66+)	<b>✓</b>	<b>✓</b>	n/a
Care Management*	Payer-specific program requirements for CM licensure & training, billing, service thresholds. Patients must be seen for at least two CM visits, on different dates of service, to count towards engagement thresholds	See payer-specific guidelines for details; PCMH designation required	✓	<b>✓</b>	n/a
Cervical Cancer Screening*	Females ages 21-64: Cervical cytology once every 3 years (01/01/2021 - 12/31/2023) or hrHPV testing (with/without cervical cytology) once every 5 years (01/01/2019 - 12/31/2023; ages 30+ years)	Exclude pts. with hysterectomy leaving no residual cervix and pts. in hospice or palliative care. Required documentation includes: "no residual cervix," "total", "radical" or "complete" hysterectomy	<b>✓</b>	<b>✓</b>	n/a
Child and Adolescent Well-Care Visits <sup>+</sup>	Ages 3-21 years: At least one well-care visit with PCP or OB/GYN in 2023 PH: rate for ages 3-11 only; BCBSM: rates for all ages	Documentation must include date and physical exam; patient-reported height and weight acceptable; Visits may be completed via telehealth (bill with GT or 95 modifier, POS 02 or POS 10)	✓	<b>√</b>	n/a
Chlamydia Screening <sup>+</sup>	Sexually-active female patients ages 16-24: One Chlamydia screening test (01/01/2023 - 12/31/2023)	Definition of "sexually active": Footnote #1	<b>√</b>	<b>√</b>	n/a
Colorectal Cancer Screening <sup>+</sup>	Ages 45-75: 1 home FOBT (01/01/2023 - 12/31/2023 <u>OR</u> 1 flexible sigmoidoscopy (01/01/2019 - 12/31/2023) <u>OR</u> 1 colonoscopy (01/01/2014 - 12/31/2023) <u>OR</u> 1 FIT-DNA (Cologuard; 01/01/2021 - 12/31/2023) OR 1 CT Colonography (01/01/2019 - 12/31/2023)	Exclude pts. with Dx of colorectal cancer or history of total colectomy, those residing in long-term care, in hospice or palliative care, or with Frailty and Advanced Illness diagnoses. Documentation must include date (year), type of test, & result/findings (e.g., Normal/Abnormal)	<b>√</b>	<b>√</b>	n/a



Measure Name	Description	Details	BCBSM/BCN (PGIP, PCMH, VBR, PRP)	Priority Health (PIP)	ACO REACH
Controlling High Blood Pressure*	Ages 18-85 with Dx of HTN: Most recent BP reading in 2023 is adequately controlled (systolic BP < 140 AND diastolic BP < 90); Two outpatient visits with Dx of HTN required (01/01/2022 - 06/30/2023)	Exclude pts. with ESRD, dialysis, nephrectomy, kidney transplant, pregnancy, in hospice, palliative or long-term care, or those with both Frailty AND Advanced illness (age 66-80 yrs.) or Frailty alone (age 81+); Patient-reported BP readings acceptable if taken by a digital device	<b>~</b>	<b>√</b>	n/a
Diabetes: Blood Pressure Control**	Ages 18-75 with Dx of DM (Type I or Type II): Most recent BP value in 2023 must be < 140/90	Exclude pts. with PCOS or gestational/steroid-induced DM, in hospice, palliative, or long-term care, or with both Frailty and Advanced Illness	<b>√</b>	n/a	n/a
Diabetes: HbA1c Control <sup>+</sup>	Ages 18-75 with Dx of DM (Type I or Type II): Most recent HbA1c lab value in 2023 must be < 8 (BCBSM only) and/or $\leq$ 9 (BCBSM, PH)	Exclude pts. with PCOS or gestational/steroid-induced DM, in hospice, palliative, or long-term care, or with both Frailty and Advanced Illness	<b>✓</b>	<b>√</b>	n/a
Diabetes: Kidney Health Evaluation*	Ages 18-85 with Dx of DM (Type I or Type II): One urine eGFR and one albumin- creatinine ratio test; PH Medicare patients only	Exclude pts. with ESRD, dialysis, PCOS or gestational/steroid-induced DM, in hospice, palliative or long-term care, or those with both Frailty and Advanced Illness (age 66-80) or Frailty alone (age 81+)	n/a	<b>√</b>	n/a
Diabetes: Retinal Eye Exam <sup>+</sup>	Ages 18-75 with Dx of DM (Type I or Type II): Retinal eye exam in 2023 or negative exam (no evidence of retinopathy) in 2022	"Bilateral eye enucleation" is an indicator that a retinal eye exam was done; Documentation must include date and type of exam (i.e., dilated, retinal), result (positive or negative for retinopathy) and name of eye care professional performing/interpreting exam	<b>✓</b>	<b>√</b>	n/a
Follow-Up After Emergency Department Visit for Mental Illness	Ages 6-17: Outpatient follow-up visit, within 7 days of an ED visit (01/01/2023 - 12/01/2023) with a principal Dx of Mental Illness or Intentional Self-Harm	Exclude patients in hospice and ED visits with an inpatient admission on or within 30 days of DOS; Follow-up visits include telehealth, telephone, evisit, or virtual check-in. Claims-based	<b>√</b>	n/a	n/a
Follow-Up after Emergency Department Visit for People with Multiple High-Risk Chronic Conditions**	Ages 18+ years with ≥ 2 chronic disease conditions (COPD/Asthma, Alzheimer's Disease/Dementia, CKD, Depression, HF, AMI, A-Fib, Stroke/TIA) and an ED visit in 2023: Pt. seen for follow-up within 7 days of ED visit	Exclude ED visits resulting in admission and pts. In hospice	~	n/a	n/a
Follow-Up Care for Children Prescribed ADHD Medication	Ages 6-12: One visit within 30 days of new ADHD Rx (Initiation Phase). THEN, medication adherence plus 2 visits within days 31-300 (Continuation & Maintenance Phase)	Telehealth and telephone visits are allowed for both phases Exclusions: Footnote #2	<b>✓</b>	n/a	n/a
Frailty and Advanced Illness Exclusion Criteria	Frailty and Advanced Illness Exclusion Criteria: Ages 66+ years: $\geq$ 2 indications of Frailty in 2023 AND one of the following in 2022 or 2023: $\geq$ 2 outpatient or non-acute inpatient visits, or $\geq$ 1 acute inpatient visit, with an Advanced Illness Dx OR dispensed a Dementia medication	Frailty Alone Exclusion Criteria: Ages 81+ years: ≥2 indications of Frailty in 2023	<b>~</b>	<b>√</b>	n/a
Immunizations: Adolescent*, HPV**	Patients turning age 13 in 2023: Completed Combination 2 vaccine series (meningococcal conjugate, Tdap, and HPV) by time of 13th birthday (BCBSM, PH). Additional, separate incentive for HPV component (BCBSM)	Data pulled from claims and downloaded from MCIR	✓	<b>√</b>	n/a
Immunization: Childhood <sup>+</sup>	Patients turning age 2 in 2023: Completed Combination 10 (BCBSM) or Combination 3 (Priority Health) vaccine series by time of 2nd birthday	Data pulled from claims and downloaded from MCIR	✓	✓	n/a
Lead Screening*	Patients turning age 2 in 2023: One blood test screening for lead poisoning completed by time of 2nd birthday	Data pulled from claims or entered as supplemental data	n/a	✓	n/a



Measure Name	Description	Details	BCBSM/BCN (PGIP, PCMH, VBR, PRP)	Priority Health (PIP)	ACO REACH
Low Back Pain: Use of Imaging Studies	Ages 18-75 with primary Dx of Low Back Pain: Imaging studies NOT performed within 28 days of Dx (For patients with no claims/encounters with any Low Back Pain Dx	Inverse measure (lower Numerator is better); Exclude pts. with Hx of cancer, trauma, IV drug abuse, neurologic impairment, prolonged use of corticosteroids, HIV, major organ transplant, spinal infection, Osteoporosis Rx, fragility fracture, lumbar surgery, spondylopathy, having both Frailty and Advanced Illness (ages 66+), or in hospice/palliative care	<b>~</b>	n/a	n/a
Medication Adherence for Cholesterol <sup>+</sup> , Diabetes <sup>+</sup> and Hypertension <sup>+</sup>	Ages 18 years and older: Adherence (80% PDC) to oral DM medication, ACE/ARB or direct renin inhibitor (HTN), or statin (Cholesterol)	Proportion of Days Covered (PDC) is percent of days in measurement year "covered" by prescription claims for medication or another in therapeutic category. Exclusions: Footnotes #3 & #4	n/a	<b>*</b>	n/a
Pediatric Weight Management	Ages 5-17: Initial Dx of Ever Obese (Z68.54) and subsequent Dx of No Longer Obese (Z68.51-Z68.53); 1% PDCM engagement threshold required for measure eligibility (pediatric practices only)	2-year measurement period (01/01/2022 - 12/31/2023); Payable as PDCM Outcomes VBR	<b>✓</b>	n/a	n/a
Risk of Continued Opioid Use-15 Days**	days covered by a prescription opioid medication.	Exclude pts. with Cancer, Sickle Cell Disease, or in hospice or palliative care. Does not apply to injectable opioids, opioid-containing cough/cold products, fentanyl transdermal patches, or meds used to treat Opioid Use Disorder (Methadone, Buprenorphine)	~	n/a	n/a
Social Determinants of Health <sup>+</sup>	Patients with E&M visit in 2023: Positive screen for a Social Determinants of Health need; Bill SDoH Z-codes for 5% of unique, insurer-specific patients	Claims-based; Practice must be PCMH-designated. BCBSM: Practice-level target; PH: NPO-level target	✓	✓	n/a
Statin Therapy for Patients with Cardiovascular Disease <sup>+</sup>	Males ages 21-75 and Females ages 40-75 with Dx of ASCVD : one statin medication (high or moderate intensity) dispensed during 2023	Pharmacy claims-based; Only Statins (NOT other cholesterol-lowering medications) meet Numerator criteria; Exclusions: Footnote #5	✓	✓	n/a
Statin Therapy for Patients with Diabetes	Ages 40-75 with Diabetes but not ASCVD: Dispensed at least one statin medication (any intensity) during 2023	Exclude pts. with cardiovascular disease, PCOS or gestational/steroid- induced DM, pregnancy/in vitro fertilization, Cirrhosis, Myalgia, Myositis, Myopathy, Rhabdomyolysis, ESRD/dialysis, in hospice or palliative care, or with Frailty and Advanced illness	~	n/a	n/a
Statin Use in Persons with Diabetes*	Ages 40-75 and dispensed at least two Diabetes medication fills: Received at least one statin medication fill (any intensity) in 2023; Medicare patients only	Exclude patients with ESRD or dialysis, PCOS, Rhabdomyolysis, Myopathy, Myositis, Pre-Diabetes, Liver Disease, Pregnancy/Lactation, or in hospice in 2023	<b>√</b>	<b>~</b>	n/a
Transitions of Care: Medication Reconciliation Post-Discharge	Ages 18 and older with inpatient discharge (01/01/2023 -12/01/2023): Medications were reconciled on or within 30 days of discharge; BCBSM/BCN Medicare patients only	Med Rec done by prescribing provider, pharmacist or RN. Acceptable documentation: current med list with notation that discharge meds were reviewed & reconciled, "no change in meds since discharge", "same meds at discharge" or "discontinue all discharge meds"; Can be completed via telehealth or telephone. Submit code 1111F on claim when completed	<b>~</b>	n/a	n/a
Transitions of Care: Patient Engagement	engagement provided within 30 days of discharge; BCBSM/BCN Medicare patients	Exclude patients in hospice or using hospice services; Engagement includes outpatient, telephone, or telehealth visits, e-visits or virtual check-ins; Requires interaction with patient or care giver	<b>√</b>	n/a	n/a
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents	Ages 3-17 with PCP or OB/GYN visit in 2023: Documentation of BMI percentile (including ht. & wt.), and counseling for nutrition and physical activity	Use billing codes or enter data into Health-e Blue; BMI percentile must be documented as distinct value, not range	<b>~</b>	n/a	n/a



Measure Name	Description	Details	BCBSM/BCN (PGIP, PCMH, VBR, PRP)	Priority Health (PIP)	ACO REACH
Months of Life <sup>+</sup>	Children turning 15 months old in 2023: 6 or more well-child visits with PCP before birthday (BCBSM & PH) Children turning 30 months old in 2023: 2 or more well-child visits with PCP before birthday (BCBSM only)	Claims-based	✓	<b>~</b>	n/a
	HOSPITAL BASED AND/OR ORGANIZATION	ON ADMINISTRATIVE MEASURES			
Patients with Multiple Chronic	DCE-aligned beneficiaries, age 66 and older, with multiple chronic conditions (AMI, Alzheimer's/Dementia, A-Fib, CKD, COPD/Asthma, Depression, Heart Failure, Stroke/TIA, Diabetes): rate of acute, unplanned hospital admissions in 2023	Event-based, claims-dependent measure; Exclude planned admissions, admits from SNF, rehab, hospice or related to accidents, injuries or surgeries. Pt. must be established with an ACO REACH PCP	n/a	n/a	<b>✓</b>
CAHPS**	Ages 18+ years with Medicare plan (BCBSM or ACO REACH-aligned) and at least two primary care visits in past 12 months: Answers patient experience survey questions	Survey administered by CAHPS survey vendor; Exclude pts. that are institutionalized, in hospice, reside outside of US, or with disability barrier preventing survey completion	<b>√</b>	n/a	<b>✓</b>
РСМН	VBR available to PCMH-designated practices (BCBSM); PCMH designation required for incentive program participation (BCBSM $\&$ PH)	Contact NPO for details	✓	✓	n/a
Plan All-Cause Readmissions	Ages 18+ years and with an acute inpatient or Observation stay in 2023: Rate of readmission, for any Dx, occurring within 30 days of discharge; Applies to BCBSM Medicare Advantage pts.	Event-based and claim-dependent; Exclude non-acute admissions, planned stays for rehab, chemotherapy or organ transplant, pregnancy-based stays or stays ending in patient death	<b>√</b>	n/a	n/a
Risk-Standardized All-Condition Readmissions	ACO REACH-aligned beneficiaries, age 65+ years: Rate of unplanned hospital readmission, within 30 days of discharge from index admission, in 2023	Event-based and claim-dependent; Exclude pts. with Dx of Cancer or mental illness, in rehab, with planned readmissions or transferred to another acute care hospital, and those discharged AMA	✓	n/a	<b>✓</b>
Timely Follow-Up After Acute Exacerbations of Chronic Conditions	IA(() RFA(H-aligned heneticiaries: Rate of follow-up for natients experiencing acute	Event-based and claim-dependent; Exclude pts. in SNF or hospice (Pts. In psychiatric, rehab, or long-term care facilities are INCLUDED in this measure). Follow-up visits may be face-to-face or telehealth, office/home visits, CCM services, TCM encounters; Follow-up time frames: Footnote #6	n/a	n/a	✓

<sup>\*</sup>Priority Health: Performance rates are calculated, and target thresholds must be met, at the ACN-level; practice-level scoring has been discontinued

- 1. Females identified sexually-active from pharmacy claims data (e.g., Rx for contraceptives dispensed) and/or claims/encounter data (codes pertain to pregnancy, pregnancy testing or STD testing/disease)
- 2. Exclude patients with inpatient admission for mental health or chemical dependency (within 30-300 days after the ADHD Rx start date), those with Dx of Narcolepsy as of 12/31/2023, or those in hospice in 2023
- 3. Exclude patients with one or more insulin fills or with a Rx of sacubitril/valsartan from the DM and HTN med adherence measures, respectively
- 4. Patients with Dx of ESRD or dialysis, or in hospice or utilizing hospice services, are excluded from all three Medication Adherence measures
- 5. Exclude patients: with Dx of ESRD/dialysis, Cirrhosis, Rhabdomyolysis, Myalgia, Myositis, Myopathy, pregnancy, in vitro fertilization (IVF) or Rx for Clomiphene, patients in hospice, palliative or long-term care, pts. with both Frailty AND Advanced Illness (age 66+)
- 6. Follow-up timeframes: HTN -14 days (high-acuity or 30 days (medium-acuity); Asthma, Diabetes, or HF -14 days; CAD 7 days (high-acuity) or 6 weeks (low-acuity); COPD 30 days

Sources: 2023 ACO REACH Quality Strategy Paper; 2023 ACO Reach Quality Kick-Off Webinar (CMS slide deck); 2023 ACO Realizing Equity, Access, and Community Health (REACH) Model Measure Information Forms (All-Cause Unplanned Admissions for Patients with Multiple Chronic Conditions; Risk-Standardized, All-Condition Readmission; Timely Follow-Up After Acute Exacerbations of Chronic Conditions); 2023 CMS Medicare 5 Star Manual (Medicare 2023 Part C & D Star Ratings Technical Notes); 2023 HEDIS Provider Guide (Priority Health); 2023 PCP Incentive Program (PIP) Final Manual (Priority Health); 2023 PDCM OVBR Metrics (BCBSM document); 2023 PGIP Clinical Quality Initiative (BCBSM document); 2023 Quality Rewards Measures: PRP, CLQI and CQ-VBR (BCBSM/BCN document); 2023 Provider-Delivered Care Management (PDCM) for 2024 Value-Based Reimbursement (VBR) (BCBSM document); 2023 Updates to Patient Experience and Quality (BCBSM/BCN Slide Deck); HEDIS Measurement Year 2023 Volume 2: Technical Specifications for Health Plans; HEDIS MY 2023 Volume 2 Value Set Directory; SUPD-SPC Exclusionary Codes Update (Priority Health, 05/17/2022); PGIP Quarterly Meeting: PGIP Organizational Update - "SDOH Initiative Updates for VBR Effective September 1, 2024" (09/16/2022 Presentation)

<sup>\*\*</sup>New measure for 2023